摘要
目的通过对葛根素辅助治疗肿瘤或癌症的文献进行可视化分析,得到葛根素在肿瘤或癌症上的临床应用范围及研究热点;进而通过生物信息学技术切入有效成分葛根素探讨其潜在的安全风险。方法通过系统整理有关葛根素预防癌症的有关资料,并利用CiteSpace软件,在文献数据库中检索自1990年1月1日至2022年10月31日有关葛根素预防肿瘤和癌症的有关资料进行了可视化分析,探索葛根素在癌症预防方面的医学应用意义;同时通过利用生物技术,对GEO数据库中的GSE85871基因芯片进行了检测和研究,对人乳腺癌细胞MCF7中的差异表达基因进行了GO功能注释研究和KEGG通路研究。结果基于可视化分析结果,葛根素在肝癌、肺癌、宫颈癌、膀胱癌、卵巢癌以及乳腺癌等病症的领域研究较多。但生物信息研究结果也表明,在应用葛根素辅助治疗乳腺癌中,葛根素会作用于cGMP信号通路、神经配体-受体相互作用信号通路,影响催产素分泌和破骨细胞分化,对心血管系统、神经系统和骨骼代谢可能存在潜在的安全风险。结论尽管葛根素在对肝癌、肺癌、宫颈癌等疾病的辅助治疗上有着潜在的使用意义,但在乳腺癌辅助治疗时则必须充分考虑其不良反应,应加强对含葛根素中药的合理应用研究,以确保其安全有效地使用。
Objective To study the clinical applicability and hotspots of research of puerarin and to identify the potential risks to safety.Methods Based on exhaustive analysis of data on the anti-cancer properties of puerarin and using CiteSpace software,visual analysis was conducted by searching databases for the data on the prevention of tumors and cancer by puerarin that was published between January 1,1990 and October 31,2022.At the same time,the GSE85871 gene chip in GEO database was detected and studied using biotechnology while the GO function annotation and KEGG pathway of differentially expressed genes in human breast cancer cell MCF7 were explored.Results Visual analysis suggested that the role of puerarin in treating liver cancer,lung cancer,cervical cancer,bladder cancer,ovarian cancer,breast cancer and other diseases had been extensively studied.However,the results of bioinformatics research also showed that when puerarin was used in adjuvant treatment of breast cancer,puerarin tended to act on the cGMP signaling pathway and the nerve ligand receptor interaction signaling pathway,thus affecting oxytocin secretion and osteoclast differentiation.There might be potential safety risks to the cardiovascular system,nervous system and bone metabolism.Conclusion Despite the utility of puerarin in the adjuvant treatment of cancers,the related adverse reactions have to be taken into consideration,and rational use of traditional Chinese medicines containing puerarin should be recommended to ensure safe and effective use.
作者
刘亚迪
王雪
殷晓阳
刘泽宇
张晓朦
张冰
林志健
LIU Yadi;WANG Xue;YIN Xiaoyang;LIU Zeyu;ZHANG Xiaomeng;ZHANG Bing;LIN Zhijian(School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 102488 China)
出处
《中国药物警戒》
2023年第12期1407-1414,共8页
Chinese Journal of Pharmacovigilance
基金
国家自然科学基金资助项目(82274117)
国家中医药管理局中医药创新团队及人才支持计划子项(No.ZYYCXTD-C-202005-11)。
